Harm Reduction· Daily Pulse

DEA Says the Drug Supply Has Outpaced Naloxone Again — This Time It's Cychlorphine

A May 12 public safety advisory names four substances now common in the illicit supply, three of which complicate or defeat overdose reversal.

ByThe Rize NewsroomMay 21, 20262 min readNovel & Emerging Psychoactives

DEA Says the Drug Supply Has Outpaced Naloxone Again — This Time It’s Cychlorphine

The day before the CDC released its 2025 overdose-decline numbers, the DEA’s Detroit Field Division issued a public safety advisory on what is now routinely mixed into the illicit drug supply. Four substances are named: xylazine, medetomidine, nitazenes, and cychlorphine. The first two are veterinary sedatives — not opioids — and naloxone does not reverse their effects. The second two are non-pharmaceutical synthetic opioids; naloxone reverses them, but may require multiple doses to be effective.

Cychlorphine is the newest. The Center for Forensic Science Research and Education flagged it in a January 2026 public alert as the suspected cause of fatal overdoses across at least eight states, with in vitro potency estimated at roughly ten times that of fentanyl. The compound’s emergence appears to track a supply-substitution pattern: after China placed nitazene analogues under generic control in July 2025, nitazene positivity in fatal-overdose toxicology declined — while cychlorphine positivity rose to fill the gap.

What this changes about overdose response

For practical purposes, the harm-reduction script has not changed. Carry naloxone. Carry more than one dose. Call 911. Do not use alone. Begin rescue breathing if needed. But the American Academy of Family Physicians editorial on medetomidine is a useful read for anyone — clinician or family member — designing an overdose-response plan in 2026: the duration of a withdrawal or dose response may be longer and more complex than the fentanyl-only era taught us to expect.

Why this matters for people in recovery

It is harder to use any substance “safely” today than it was three years ago. That is not a moral statement; it is a chemistry one. If you are using, the supply is changing under your feet. If you are in recovery and worried about someone you love, the most useful gift in your house right now is two doses of naloxone, two pairs of eyes, and a phone within reach. Do not assume one dose, one call, or one quick reversal is enough.

Need help right now?

Crisis & suicide: 988 Suicide & Crisis Lifeline
Free naloxone in AZ: Sonoran Prevention Works
Drug-checking and harm reduction: National Harm Reduction Coalition
Find treatment: Rize Recovery

Sources Cited

Filed Under

harm-reductionbiologytrendsNaloxone

More from this section

Harm Reduction

69,973 Deaths. The Number That Proves Harm Reduction Works—and the Policy Quietly Undoing It.

CDC provisional data projects 69,973 overdose deaths for 2025—a 13.9% decline. The same spring, SAMHSA ended federal funding for fentanyl test strips. The drug supply has never been more dangerous.

Harm Reduction

Responding to the Emerging Threat of Xylazine

On April 24, SAMHSA banned federal funding for fentanyl, xylazine, and medetomidine test strips for public distribution — precisely as the June 2026 Labcorp report shows medetomidine in 91% of Philadelphia's fentanyl supply. The policy contradiction that kills people who use drugs.

Harm Reduction

The Drug Inside the Drug: How Medetomidine Is Breaking Every Overdose Response Playbook

Medetomidine, a veterinary sedative 200 times more potent than xylazine, has displaced xylazine in Philadelphia's fentanyl supply and is confirmed in nine states. It produces sedation that naloxone cannot reverse, withdrawal that requires ICU-level care in 91% of hospitalized patients, and clinical presentations that emergency departments are consistently misidentifying.